PINEHURST – A FirstHealth Moore Regional Hospital clinical trial is investigating whether the electrical treatment provided by a special type of pacemaker can keep a patient in heart failure from getting worse.
The Cardiac Resynchronization Therapy (CRT) pacemaker being studied in this clinical trial has been approved by the U.S. Food and Drug Administration (FDA) for patients with moderate to severe heart failure whose heart pumps blood inefficiently. The study will determine if blood can be pumped to the body more efficiently when the lower heart chambers (i.e. ventricles) are electrically paced to beat together by the CRT pacemaker.
Cardiac resynchronization therapy (CRT) can help restore a normal coordinated heart rhythm by delivering pacing treatment to both sides of the heart.
Participants in the trial will be men and women 18 years and older with a diagnosis of chronic heart failure. Pregnant women are not eligible.
Mark Landers, M.D., a cardiologist with FirstHealth Cardiology Services, is the principal investigator.
To refer a patient for this trial or for more information on patient eligibility, contact the FirstHealth Clinical Trials office at (910) 715-2200.
December 1, 2016
Montgomery County Schools First in Nation to Implement Daily Mile ProgramRepresentatives of the various agencies involved in the Montgomery County implementation of The Daily Mile prepare to cut the ribbon for the walking…
March 22, 2016
Women’s Health Topics to Highlight FirstHealth “Girl Talk” ProgramPINEHURST – Heart, breast and bone health are among the most-discussed women’s health topics of today, and each will be highlighted during the upcomi…
December 29, 2015
Five Tips for the New YearYear after year we make resolutions to exercise regularly, eat well, give up smoking and other bad habits. But most of us fail to keep our promises t…
May 31, 2018
31st Annual National Cancer Survivors DayNational Cancer Survivors Day is a time to come together and share smiles and victories. Join us in our celebration of life and triumph over cancer!…